Investigational drug · Phase 2
SSS17
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Postoperative Anemia, Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 18, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
6
Any phase or sponsor naming "SSS17"
First trial start
2023
Mar 1, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SSS17", any sponsor or status.
Conditions studied
As listed on its trial records.
- Postoperative Anemia
- Arthroplasty, Replacement, Hip
- Arthroplasty, Replacement, Knee
- Anemia in Pre-Dialysis Patients
Approved drugs for the same conditions: Anemia · Hematology and blood cancers · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "SSS17" as an intervention, largest first.
- Phase IIa Trial of Oral SSS17 for Post-Arthroplasty AnemiaNot yet recruiting
Shenyang Sunshine Pharmaceutical Co., LTD.Industry
NCT07007936 · 90 participants (planned) · Start Jul 2025 · Primary completion Apr 2026
Drug: SSS17 Capsule (6 Dose Levels); Placebo Drug · For: Postoperative Anemia; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee
Sites: Beijing, China
Shenyang Sunshine Pharmaceutical Co., LTD.Industry
NCT07014631 · 86 participants · Start Mar 1, 2023 · Primary completion Dec 12, 2024
Drug: SSS17; Placebo · For: Anemia in Pre-Dialysis Patients
Sites: Beijing, China
- A Phase 1 Study of SSS17 in Healthy Subjects.Status unknown
Shenyang Sunshine Pharmaceutical Co., LTD.Industry
NCT04893187 · 76 participants (planned) · Start Jul 26, 2021 · Primary completion Dec 31, 2022
Drug: SSS17; Placebo · For: Anemia in Chronic Kidney Diseases
Sites: Guangzhou, China
- A Study of SSS17 in Healthy SubjectsStatus unknown
Shenyang Sunshine Pharmaceutical Co., LTD.Industry
NCT04317833 · 65 participants (planned) · Start May 1, 2020 · Primary completion Jun 30, 2021
Drug: SSS17; Placebo · For: Anemia in Chronic Kidney Diseases
Sites: Shanghai, China
Shenyang Sunshine Pharmaceutical Co., LTD.Industry
NCT07024888 · 36 participants · Start Mar 16, 2025 · Primary completion May 28, 2025
Drug: SSS17 · For: Healthy Subjects (HS)
Sites: Qingdao, China
- A Phase 1 Mass Balance Study of [¹⁴C]SSS17 in Healthy Chinese MalesNot yet recruiting
Shenyang Sunshine Pharmaceutical Co., LTD.Industry
NCT07025915 · 6 participants (planned) · Start Jun 2025 · Primary completion Jul 2025
Drug: [14C]SSS17 · For: Healthy Subjects (HS)
Newest research
PubMed records naming it or its code names, newest first.
- Defective gating of the Sec61 translocon results in reorganisation of the actin cytoskeleton and perturbed formation of the actomyosin contractile ring.
Thomasson LV, Witham CM, Steuart RFL, et al. · Biochim Biophys Acta Mol Cell Res 2025
- Detection of quantitative trait loci affecting serum cholesterol, LDL, HDL, and triglyceride in pigs.
Uddin MJ, Duy do N, Cinar MU, et al. · BMC Genet 2011
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.